208 related articles for article (PubMed ID: 20427935)
21. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
Brenner B; Wiis J
Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
[TBL] [Abstract][Full Text] [Related]
22. [The use of recombinant activated factor VII for blood loss after cardiovascular surgery].
Gong ZY; Gao CQ; Xiao CS; Li BJ; Ma XH; Zhang CM
Zhonghua Wai Ke Za Zhi; 2008 Oct; 46(19):1497-501. PubMed ID: 19094631
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of recombinant factor VIIa treatment for massive hemorrhage in patients with multiple traumas.
Koh YR; Cho SJ; Yeom SR; Chang CL; Lee EY; Son HC; Kim HH
Ann Lab Med; 2012 Mar; 32(2):145-52. PubMed ID: 22389882
[TBL] [Abstract][Full Text] [Related]
24. Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry.
Phillips LE; McLintock C; Pollock W; Gatt S; Popham P; Jankelowitz G; Ogle R; Cameron PA;
Anesth Analg; 2009 Dec; 109(6):1908-15. PubMed ID: 19923520
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of using recombinant activated factor VII as an off-label rescue treatment for critical bleeding requiring massive transfusion.
Ho KM; Litton E
Transfusion; 2012 Aug; 52(8):1696-702. PubMed ID: 22211634
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of recombinant activated Factor VII in patients with massive uncontrolled bleeding: a retrospective observational analysis.
Berkhof FF; Eikenboom JC
Transfusion; 2009 Mar; 49(3):570-7. PubMed ID: 19040498
[TBL] [Abstract][Full Text] [Related]
27. Recombinant activated factor VII use in critically ill infants with active hemorrhage.
Jen H; Shew S
J Pediatr Surg; 2008 Dec; 43(12):2235-8. PubMed ID: 19040942
[TBL] [Abstract][Full Text] [Related]
28. "Low-dose" recombinant activated factor VII results in less blood and blood product use in traumatic hemorrhage.
Harrison TD; Laskosky J; Jazaeri O; Pasquale MD; Cipolle M
J Trauma; 2005 Jul; 59(1):150-4. PubMed ID: 16096555
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of recombinant activated factor VII for refractory hemorrhage in pediatric patients on extracorporeal membrane oxygenation: a single center review.
Long MT; Wagner D; Maslach-Hubbard A; Pasko DA; Baldridge P; Annich GM
Perfusion; 2014 Mar; 29(2):163-70. PubMed ID: 23942787
[TBL] [Abstract][Full Text] [Related]
30. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes.
MacLaren R; Weber LA; Brake H; Gardner MA; Tanzi M
Transfusion; 2005 Sep; 45(9):1434-42. PubMed ID: 16131375
[TBL] [Abstract][Full Text] [Related]
31. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma.
Martinowitz U; Kenet G; Lubetski A; Luboshitz J; Segal E
Can J Anaesth; 2002 Dec; 49(10):S15-20. PubMed ID: 12546003
[TBL] [Abstract][Full Text] [Related]
32. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors.
Santagostino E; Mancuso ME; Rocino A; Mancuso G; Scaraggi F; Mannucci PM
J Thromb Haemost; 2006 Feb; 4(2):367-71. PubMed ID: 16420567
[TBL] [Abstract][Full Text] [Related]
33. Reduced mortality by meeting guideline criteria before using recombinant activated factor VII in severe trauma patients with massive bleeding.
Payen JF; Berthet M; Genty C; Declety P; Garrigue-Huet D; Morel N; Bouzat P; Riou B; Bosson JL;
Br J Anaesth; 2016 Oct; 117(4):470-476. PubMed ID: 28077534
[TBL] [Abstract][Full Text] [Related]
34. Characteristics Associated With Mortality in 372 Patients Receiving Low-Dose Recombinant Factor VIIa (rFVIIa) for Cardiac Surgical Bleeding.
Baral P; Cotter E; Gao G; He J; Wirtz K; Sharma A; Zorn Iii T; Muehlebach G; Flynn B
J Cardiothorac Vasc Anesth; 2019 Aug; 33(8):2133-2140. PubMed ID: 30772178
[TBL] [Abstract][Full Text] [Related]
35. Recombinant factor VIIa: unregulated continuous use in patients with bleeding and coagulopathy does not alter mortality and outcome.
Ganguly S; Spengel K; Tilzer LL; O'neal B; Simpson SQ
Clin Lab Haematol; 2006 Oct; 28(5):309-12. PubMed ID: 16999720
[TBL] [Abstract][Full Text] [Related]
36. Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage.
Brady KM; Easley RB; Tobias JD
Paediatr Anaesth; 2006 Oct; 16(10):1042-6. PubMed ID: 16972833
[TBL] [Abstract][Full Text] [Related]
37. Early versus late recombinant factor VIIa in combat trauma patients requiring massive transfusion.
Perkins JG; Schreiber MA; Wade CE; Holcomb JB
J Trauma; 2007 May; 62(5):1095-9; discussion 1099-101. PubMed ID: 17495707
[TBL] [Abstract][Full Text] [Related]
38. Recombinant factor VIIa is associated with an improved 24-hour survival without an improvement in inpatient survival in massively transfused civilian trauma patients.
Nascimento B; Lin Y; Callum J; Reis M; Pinto R; Rizoli S
Clinics (Sao Paulo); 2011; 66(1):101-6. PubMed ID: 21437444
[TBL] [Abstract][Full Text] [Related]
39. A Comparison of Prothrombin Complex Concentrate and Recombinant Activated Factor VII for the Management of Bleeding With Cardiac Surgery.
Katz A; Ahuja T; Arnouk S; Lewis TC; Marsh K; Papadopoulos J; Merchan C
J Intensive Care Med; 2022 Feb; 37(2):231-239. PubMed ID: 33402016
[TBL] [Abstract][Full Text] [Related]
40. Adequacy of hemostatic resuscitation improves therapeutic efficacy of recombinant activated factor VII and reduces reexploration rate for bleeding in postoperative cardiac surgery patients with refractory hemorrhage.
Feih JT; Juul JJ; G Rinka JR; Baumann Kreuziger LM; Pagel PS; Tawil JN
Ann Card Anaesth; 2019; 22(4):388-393. PubMed ID: 31621674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
